

# Is NEMA clinically relevant?


---

Joel Karp  
Department of Radiology  
University of Pennsylvania




# Overview

- Review of NEMA NU2
- Does NEMA need update for new technology?
- Is NEMA relevant for clinical imaging?
- Are NEMA tests relevant for quantitative clinical trials?

2001 phantom is better predictor than 1994 phantom of whole-body study count rates




# Can we optimize patient protocol with image quality phantom (NEMA 2001)?



# Image quality depends on patient weight

*Philips Allegro*




Slim 58 kg

“Normal” 89 kg



Heavy 127 kg

Object diameter	Relative attenuation	Peak Trues ratio	Peak NEC ratio	Peak NEC density ratio
20 cm	1	3.4	6	18
27 cm	2.2	2	2.7	4.5
35 cm	4.3	1	1	1

# BMI distribution



# Count-rate Measurement




35 cm


27 cm

20 cm

NEMA NU2



$$NEC' = \frac{(T + Sc) \times (T + Sc)}{T + Sc + R} = \frac{(P - D)^2}{P}$$



- Patients scanned 60 min. post-injection of 555 MBq (15 mCi) of <sup>18</sup>F-FDG
  - 20 cm diameter
  - 27 cm diameter
  - 35 cm diameter
- } Phantoms

# Beta testing of Gemini TF TOF PET/CT

- IRB modification: scan Gemini TF following Allegro
- Gemini scan start > 2 hours post-inj, 3 minutes/bed

	crystal	$E_{\text{thresh}}$	Scatter	AC	Recon
<b>Allegro</b>	GSO 4x6x20mm <sup>3</sup> 18cm $A_{\text{FOV}}$	410 keV	BG-sub	<sup>137</sup> Cs	3D RAMLA
<b>Gemini</b>	LYSO 4x4x22mm <sup>3</sup> 18cm $A_{\text{FOV}}$	440 keV	SSS model	CT	LM-EM OSEM <b>TOF</b>


# Lymphoma

39 yo woman


64 kg

BMI = 24.1

Allegro



Gemini TF




Colon cancer

73 yo woman


119 kg

BMI = 46.5

Allegro




Gemini TF




# Rectal carcinoma, metastases in mesentery and bilateral iliac chains

63 yo woman  
114 kg  
BMI = 38.1


Data acquired with Gemini TF  
Reconstructed with 4 algorithms




3D Ramla  
non-TOF



LOR Ramla  
non-TOF




List-Mode EM  
non-TOF




List-Mode EM  
TOF

*Philips Gemini TF*



SSS TOF-SSS



SSS TOF-SSS

Is the total (image) equal to the sum of its parts?

Spatial resolution + SF + Sensitivity + ..... = ?


Gemini TF (LYSO)

4.8 mm

27%  
(440 keV)

6.6%

700 ps




LaPET (LaBr)

5.5 mm

18%  
(485 keV)

6%

420 ps



Same reconstruction  
TOF LM-EM

Are the NEMA tests relevant for clinical trials?

# PET/CT Applications and Challenges

Primarily for Cancer Imaging -- works very well


- Diagnostic imaging and staging for cancer

**Expanding Areas -- with significant challenges**

- Radiation treatment planning using PET and CT
- Cardiac imaging
- Assessment of therapeutic response

# Quantitative Assessment of Response to Therapy

Change in SUV measures of FDG and fluoride incorporation for bony metastases from breast cancer before (left) and after hormonal therapy (right)




*Courtesy David Mankoff U of W*


# Quantitative Assessment of Response to Therapy

"Consensus Recommendations for the Use of  $^{18}\text{F}$ -FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials" *JNM* 47(6):1059, 2006

- considered issues with patient prep and scan protocol
- issues with multicenter comparisons not resolved



Breast tumor FDG uptake vs. time Beaulieu *JNM* 44(7):1044, 2003



# What Affects PET Image Quantitation?


## Physical sources of error

- Attenuation
- Scattered and Random coincidences
- detector efficiency variations, scanner dead-time

## Sources of variability

- Patient Specific
  - Biological changes
  - Lesion size (partial volume effect)
  - Patient motion
- Imaging protocol
  - patient preparation
  - uptake period and environment
  - scan protocol: amount of FDG injected, scan duration, 2D or 3D mode, PET vs. CT order
- Processing specific
  - Reconstruction Method
  - Image smoothness vs. resolution tradeoff
  - Standardized Uptake Value (SUV) calculation
  - Display and analysis methods

# SNM $^{68}\text{Ge}$ Phantom : characterize recovery coefficient vs. sphere diameter and reconstruction method





Investigate most important effects:

- mean and max recovery coefficient
- sphere diameter
- reconstruction method
- Smoothing


Modified NEMA NU-2  
Image Quality Phantom

Sphere diameters:  
1.0, 1.3, 1.7, 2.2, 2.8, 3.7 cm

# Contrast depends on reconstruction and filter




# Contrast depends on ROI



*GE Advance, U. Wash*

# Comparison of 3 scanners



- Use of imaging data as an *in vivo* biomarker requires that quantitative, semi-quantitative and qualitative endpoints reliably reflect disease status
- Achieved by standardization of image acquisition and processing at participating sites
  - Site qualification
  - SOPs
  - Timely QA of incoming data
- Achieved by image processing and analysis at central facility under tightly controlled conditions


# ACRIN PET Credentialing

- *Submit the following for every gantry:*
  - Uniform phantom data set with SUVs
    - Fully corrected
    - Non-attenuation corrected
    - Transmission scan
  - Two anonymized wholebody patient scans
    - Fully corrected
    - Non-attenuation corrected
    - Transmission scan
  - PET qualification application form

# Measuring phantom SUVs

- “...scan the phantom with the same protocol used for patient imaging. Reconstruct the images with the same algorithm and filters used for patient imaging. Draw a circular or elliptical region of interest (ROI) covering most of the phantom’s interior over all slices. Measure and report the average SUV and standard deviation in the PET Instrument Technical Specification form. **The expected SUV for the uniform phantom is 1.0 and the acceptable range is 0.90 to 1.1.**

# Summary of Average SUVs of Accepted Cylinders




Model	# Sites	Average	St. Dev
Siemens Biograph PET/CT	32	0.98	.04
GE Discovery LS PET/CT	11	1.00	.05
GE Discovery ST PET/CT	28	1.01	.04
Philips Allegro PET	5	0.98	.09
Philips Gemini PET/CT	7	0.95	.05

- Of the first 53 sites to apply for PET qualification, 11% failed because of PET camera calibration problems.
- Numerous other sites had cylinders that initially failed due to incorrect information entered in the DICOM header

### *Most Common Mistakes*

- Incomplete submission (data or form)
- Data transmission problems (empty headers)
- Wrong weight for phantom
- Clock offsets
- Anonymization problems (over or under)
- Ge-68 cylinder-related problems

# Summary of Average Liver SUVs in Test Cases



Model	# Cases	Average	St. Dev
Siemens Biograph PET/CT	59	2.33	0.42
GE Discovery LS PET/CT	23	2.15	0.33
GE Discovery ST PET/CT	47	2.26	0.40
Philips Allegro PET	8	1.73	0.83
Philips Gemini PET/CT	12	1.78	0.46


# Summary

- Optimization of scanner
  - adjust acquisition and reconstruction parameters
  - define clinical protocols
- Difficult to predict performance for variety of patient BMI and protocols with limited number of phantoms and tests
  - task specific
- Quantification of multi-center clinical trials not resolved
  - instrument variability
  - site/user variability
  - patient/biology variability



# Filtered Backprojection

Filter trades off resolution and noise



# Iterative reconstruction

more accurate modeling of physical effects, including noise

